BOCA RATON, Fla., July 12 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) today announced that it has appointed Dr.
Matthew W. Kalnik to the role of Vice President, Business Development and
Project Management. Dr. Kalnik brings to Nabi nearly 20 years of
pharmaceutical and biotechnology experience in global drug discovery,
development and commercialization and has already made a significant impact
on Nabi's ongoing partnering and business development efforts. He is
working closely with the Nabi senior management team and pharmaceutical
research & development group to accelerate the partnership discussions for
Nabi's NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R)
(Staphylococcus aureus Polysaccharide Conjugate Vaccine) programs.
"We are extremely pleased to have Matt as a member of the
pharmaceuticals team at Nabi," said Dr. Leslie Hudson, Interim President
and Chief Executive Officer at Nabi Biopharmaceuticals. "He brings not only
a sterling track record in business development, but an impressive ability
to analyze key data and translate those analyses into market value. We
welcome him to Nabi and I personally look forward to working with him to
successfully complete the partnership and out-licensing processes we
reinvigorated in February of this year when I joined the company as Interim
CEO."
Dr. Kalnik most recently served as Executive Vice President, Head of
Business Development, at VistaGen Therapeutics, where he helped advance the
company's commercialization efforts. Prior to VistaGen, he held senior
management team positions and led business development efforts at
Genaissance Pharmaceuticals, Pharmacia, Pfizer and Daiichi Medical
Research. Dr. Kalnik also founded Hedgerow Consulting and has authored more
than a dozen primary research papers.
"I believe there is enormous potential in Nabi's NicVAX and StaphVAX
programs and I joined the company to help unlock that value through
strategic partnerships," said Dr. Kalnik. "I am excited about this
opportunity, the company's ability to maximize these assets and,
ultimately, our chance to deliver effective vaccines to the marketplace."
Dr. Kalnik is working out of Nabi's Rockville, Maryland facility and
replaced Nabi's former head of business development, Dr. Joy Barton, who
left the company to pursue other opportunities.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has one product on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Hepatitis and transplant, Gram- positive bacterial infections and
nicotine addiction. The company has recently announced the formation of the
first of two strategic business units: Nabi Biologics. Nabi Biologics has
responsibility for the company's protein and immunological products and
development pipeline, including Nabi-HB. The second business unit, Nabi
Pharmaceuticals, is expected to be formed later this year and will have
responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and
StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine)
development programs, as well as for the continuing milestone-related
clinical development obligations following the sale of PhosLo(R) (calcium
acetate). For a complete list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our Web site: http://www.nabi.com.
Forward-Looking Statements
Statements in this release that are not strictly historical are
forward- looking statements and include statements about reorganization of
our current business into two new business units, our strategic
alternatives process and clinical trials and studies. You can identify
these forward-looking statements because they involve our expectations,
beliefs, projections, anticipations or other characterizations of future
events or circumstances. These forward- looking statements are not
guarantees of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those in the
forward-looking statements as a result of any number of factors. These
factors include, but are not limited to, risks relating to our ability to:
realize anticipated cost savings related to job elimination due to greater
than anticipated severance-related costs or other factors; successfully
partner with third parties to fund, develop, manufacture and/or distribute
our existing and pipeline products, including NicVAX and our Gram- positive
infections products; obtain successful clinical trial results; our ability
to successfully complete our strategic alternatives process; generate
sufficient cash flow from sales of products or from milestone or royalty
payments to fund our development and commercialization activities; attract
and maintain the human and financial resources to commercialize current
products and bring to market products in development; depend upon third
parties to manufacture or fill our products; obtain regulatory approval for
our products in the U.S. or other markets, including approval of Nabi-HB
Intravenous; realize sales from Nabi-HB due to patient treatment protocols,
the number of liver transplants performed in HBV-positive patients and
competitive products; achieve market acceptance of our products; expand our
sales and marketing capabilities or enter into and maintain arrangements
with third parties to market and sell our products; effectively and/or
profitability use, or utilize the full capacity of, our vaccine
manufacturing facility; manufacture NicVAX or other products in our own
vaccine manufacturing facility; comply with reporting and payment
obligations under government rebate and pricing programs; raise additional
capital on acceptable terms, or at all; and re-pay our outstanding
convertible senior notes when due. Many of these factors are more fully
discussed, as are other factors, in the company's Annual Report on Form
10-K for the fiscal year ended December 31, 2006 and our Quarterly Report
for the quarter ended March 31, 2007 on Form 10-Q with the Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com/
CONTACT:
Nabi Biopharmaceuticals Investor Relations,
+1-561-989-5800
|
